Business Wire

Gemalto Launches Virtualized Network Encryption Platform to Help Customers Address Evolving Data Security Needs

Jaa

Gemalto, the world leader in digital security, today announced the launch of a new virtualized network encryption platform, SafeNet Virtual Encryptor CV1000 as part of its continued investment to address the rapidly changing data security needs of organizations worldwide.

(Gemalto will host a webinar entitled, “Network Encryption at the Flip of a Switch: Implementing Virtualized Network Encryption to Secure SD-WANs”, on June 21st at 3 p.m. Central European Time. Click here to register.)

Today, enterprises and service providers are increasingly using network functions virtualization (NFV) and software-defined networking (SDN) technologies to design, deploy and manage their networks and cloud-based services. These software-based technologies give organizations cost and operational benefits because they move network functions from dedicated network encryption hardware appliances to virtual servers. However, these technologies can also present additional security challenges for protecting sensitive data that runs across these networks because of their virtualized architecture.

Leveraging the proven security and performance of the hardware-based SafeNet High Speed Encryptor family, the SafeNet Virtual Encryptor CV1000 is a hardened virtual security appliance designed to secure data in motion across both software-defined wide area networks (SD-WAN) and traditional networks. Developed by Gemalto’s high speed encryption partner, Senetas (ASX:SEN), the SafeNet Virtual Encryptor CV1000 can encrypt data in motion at data-rates up to 5 Gbps.

“More and more organizations are embracing the advantages of virtualized networks to deliver cost-effective scalability, flexibility and network management to the network edge. Consequently, network services require trusted virtualized encryption for optimum data security,” said Todd Moore, senior vice president of Encryption Products at Gemalto. “Gemalto’s launch of a virtualized network encryption platform redefines network data security by providing the crypto-agility required to ensure sensitive data and transmissions remain secure, regardless of network design.”

Transforming the network encryption market, SafeNet High Speed Encryptors are the first to offer Transport Independent Mode, which enables organizations to encrypt data across mixed high speed WAN links (Layers 2, 3 and 4). Organizations can now be assured that they are getting the best performance and secure encryption, regardless of the network layer. This feature is currently available for the SafeNet Virtual Encryptor CV1000, and will be available for the hardware-based SafeNet High Speed Encryptors later this year.

“As organizations increasingly embrace cloud-based applications and their use of multiple network types from Ethernet to MPLS, Senetas and Gemalto are ahead of the curve in providing seamless concurrent multi-layer network traffic encryption to ensure the best in network security and performance available today,” said Andrew Wilson, CEO of Senetas.

Key Features and Benefits of the SafeNet Virtual Encryptor CV1000 include:

  • Virtualized Network Functionality reduces dependence on dedicated network encryption hardware appliances for both enterprises and network operators.
  • Reduced Cost of Ownership makes the SafeNet Virtual Encryptor CV1000 up to 10 times more affordable than hardware-based appliances.
  • Rapid Deployment and Scalability enables organizations to spin up a virtual machine to protect data across the network rather than having to physically deploy hardware at each end point.
  • Crypto-Agile Encryption Across All Network Layers with Transport Independent Mode, providing the ability to encrypt traffic across Layers 2, 3 and 4 with optimized performance and robust encryption, including support for custom algorithms.
  • Combined Encryption Key Management option, integrates with SafeNet KeySecure for enhanced key lifecycle management.

Supporting Resources

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com, or follow @gemalto on Twitter.

Contact information

Gemalto
Media:
North America
Tauri Cox, +1 512 257 3916
tauri.cox@gemalto.com
or
Europe Middle East & Africa
Sophie Dombres, +33 4 42 36 57 38
sophie.dombres@gemalto.com
or
Asia Pacific
Jaslin Huang, +65 6317 3005
jaslin.huang@gemalto.com
or
Latin America
Enriqueta Sedano, +52 5521221422
enriqueta.sedano@gemalto.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme